Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of cancer.

LEARNING OBJECTIVES

• Effectively apply results of practice-changing clinical research to the care of patients with cancer.
• Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
• Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
• Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
• Apply an awareness of new datasets and the perspectives of tumor-specific clinical investigators to refine or validate current treatment algorithms.
• Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.
• Recall ongoing trials of therapies for select hematologic cancers and solid tumors, and appropriately refer patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 17.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better, and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Neeraj Agarwal, MD, FASCO

No relevant financial relationships to disclose.

John N Allan, MD

Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: Adaptive Biotechnologies Corporation, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne.

Deborah K Armstrong, MD

Contracted Research (Clinical Trial Support): AstraZeneca Pharmaceuticals LP; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genmab US Inc.

Lyudmila Bazhenova, MD

Advisory Committees: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Natera Inc, Nuvalent, Pfizer Inc, Revolution Medicines Inc, Summit Therapeutics, Taiho Oncology Inc; Nonrelevant Financial Relationships: Alliance for Clinical Trials in Oncology Foundation.

Adam M Brufsky, MD, PhD 

Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, BriaCell, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi.

Alan H Bryce, MD

Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, MOMA Therapeutics, Novartis, Pfizer Inc; Consulting Agreements: Astellas, Johnson & Johnson; Contracted Research: Johnson & Johnson; Data and Safety Monitoring Boards/Committees: Lantheus.

Kristen K Ciombor, MD, MSCI

Advisory Committees: AbbVie Inc, Agenus Inc, ALX Oncology, BeOne, Bristol Myers Squibb, Exact Sciences Corporation, Exelixis Inc, Merck, Pfizer Inc, Summit Therapeutics, Taiho Oncology Inc, Tempus; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, BiomeaFusion Inc, Bristol Myers Squibb, Calithera Biosciences, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc, Syndax Pharmaceuticals.

Courtney D DiNardo, MD, MSCE

Advisory Committees: Astellas, Bristol Myers Squibb, Kura Oncology; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genmab US Inc, Molecular Partners, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC; Contracted Research: AbbVie Inc, Astex Pharmaceuticals, Auron Therapeutics, Remix Therapeutics, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC, SillaJen, SystImmune Inc.

Harry Paul Erba, MD, PhD

Advisory Committees: Daiichi Sankyo Inc, GlycoMimetics Inc, Kura Oncology, Sumitomo Pharma America; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GlycoMimetics Inc, Kura Oncology, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Pharma America, Taiho Oncology Inc; Contracted Research: Agios Pharmaceuticals Inc, ALX Oncology, Aptose Biosciences Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, ImmunoGen Inc, Kura Oncology, MacroGenics Inc, Novartis, Oryzon, Rigel Pharmaceuticals Inc, Sumitomo Pharma America, Taiho Oncology Inc; Speakers Bureaus: AbbVie Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals.

Terence Friedlander, MD

Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

Jonathan Goldman, MD

Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pfizer Inc, Summit Therapeutics; Contracted Research: AbbVie Inc, Agenus Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, RayzeBio, Summit Therapeutics, Tango Therapeutics.

Mrinal Gounder, MD

Consulting Agreements: Aadi Bioscience, Avacta Therapeutics, Ayala Pharmaceuticals, Ikena Oncology, Immunome, Ipsen Biopharmaceuticals Inc, Kura Oncology, Orion Corporation, Parabilis Medicines, Rain Oncology, Regeneron Pharmaceuticals Inc, SpringWorks Therapeutics Inc, Syros Pharmaceuticals Inc; Contracted Research: Avacta Therapeutics, Ayala Pharmaceuticals, Ikena Oncology, Immunome, Ipsen Biopharmaceuticals Inc, Kura Oncology, Orion Corporation, Parabilis Medicines, Pyxis Oncology, SpringWorks Therapeutics Inc, Tango Therapeutics, Vivace Therapeutics; Data and Safety Monitoring Boards/Committees: Kura Oncology.

Erika Hamilton, MD

Consulting/Advisory Roles (All Payments to Institution): Accutar Biotechnology Inc, Arvinas, AstraZeneca Pharmaceuticals LP,BeOne, Circle Pharma, Daiichi Sankyo Inc, Entos Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Jefferies LLC, Johnson & Johnson, Lilly, Medical Pharma Services SRO, Mersana Therapeutics Inc, Novartis, Pfizer Inc, Pyxis Oncology, Samsung Bioepis, Shorla Oncology, Stemline Therapeutics Inc, Tempus, Zentalis Pharmaceuticals; Research Funding (All Payments to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Accutar Biotechnology Inc, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, Aravive Inc, ARS Pharmaceuticals, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, BeOne, Black Diamond Therapeutics Inc, Bliss Biopharmaceutical (Hangzhou) Co Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Compugen, Context Therapeutics, Cullinan Therapeutics, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Duality Biologics, eFFECTOR Therapeutics Inc, Eisai Inc, Ellipses Pharma, Elucida Oncology Inc, EMD Serono Inc, Fochon Pharmaceuticals, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Inspirna, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, K-Group Beta, Kind Pharmaceuticals LLC, Leap Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Merus, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, Oncothyreon, ORIC Pharmaceuticals, Orinove Inc, Orum Therapeutics, Pfizer Inc, pharmaand GmbH, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Prelude Therapeutics, ProFound Therapeutics, Radius Health Inc, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repertoire Immune Medicines, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Stemline Therapeutics Inc, Sutro Biopharma, Syndax Pharmaceuticals, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tolmar, Transcenta, Treadwell Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc; Nonrelevant Financial Relationships: Dana-Farber Cancer Institute.

Anthony M Hunter, MD

Advisory Committees: Blueprint Medicines, Bristol Myers Squibb, Cycle Pharmaceuticals, Geron Corporation, Incyte Corporation, Novartis, PharmaEssentia, Sobi; Consulting Agreements: Blueprint Medicines, Merck, Novartis, PharmaEssentia, Sobi; Contracted Research: Ascentage Pharma, Blueprint Medicines, Cogent Biosciences, Disc Medicine, Incyte Corporation, Novartis, PharmaEssentia, Shenzhen TargetRx Inc, Sumitomo Pharma America, Syntrix Pharmaceuticals, Telios Pharma Inc; Data and Safety Monitoring Boards/Committees: Karyopharm Therapeutics.

Yelena Y Janjigian, MD

Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc; Consulting Agreements: AbbVie Inc, AlphaSights, Arcus Biosciences, ARS Pharmaceuticals, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cencora, Daiichi Sankyo Inc, Eisai Inc, Geneos Therapeutics, Gilead Sciences Inc, GSK, Guardant Health, HC Wainwright & Co, Health Advances, Imugene, Inspirna, Lilly, Lynx Health, Merck, Merck Serono, Mersana Therapeutics Inc, PeerMD, Pfizer Inc, Sanofi, Seagen Inc, Suzhou Liangyihui Network Technology Co Ltd, Zymeworks Inc; Contracted Research: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, Debbie’s Dream Foundation, eChinaHealth, ED Medresources Inc, Fred’s Team, HMP, i3Health, Imedex, Mashup Media LLC, Master Clinician Alliance, MJH Life Sciences, National Cancer Institute, OncoDaily (stock options), Paradigm Medical Communications, PeerView, Physician Education Resource (PER), Stand Up 2 Cancer, Talem Health, TotalCME, US Department of Defense, WebMD.

Kevin Kalinsky, MD, MS, FASCO

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Menarini Silicon Biosystems, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, Pfizer Inc, ProteinQure, Puma Biotechnology Inc, RayzeBio, Regor Therapeutics, Relay Therapeutics, Seagen Inc; Nonrelevant Financial Relationships (Spouse): Stock Options/Stock, Public Companies — Revolution Medicines Inc (prior employee of EQRx), ADC Therapeutics.

Manali Kamdar, MD, MBBS

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group.

Adam Kittai, MD 

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Galapagos NV, Genmab US Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, Lilly; Honoraria for Unbranded Speaking Engagements: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Lilly.

Samuel J Klempner, MD

Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EsoBiotec, Gilead Sciences Inc, I-Mab Biopharma, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Signet Therapeutics, Taiho Oncology Inc; Consulting Agreements: Astellas; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, I-Mab Biopharma, Mersana Therapeutics Inc, Parabilis Medicines; Data and Safety Monitoring Boards/Committees: Sanofi; Stock OPTIONS — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie’s Dream Foundation, Degregorio Family Foundation,Gastric Cancer Foundation, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation.

Corey J Langer, MD

Advisory Committees: Oncocyte, Summit Therapeutics; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Caris Life Sciences, Fosun Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Jazz Pharmaceuticals Inc, Merck, Novartis, Novocure Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research (Institutional Support): Advangene, Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Guardant Health, Inovio Pharmaceuticals Inc, Lilly, Merck, Navire, Novocure Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc, Trizell; Data and Safety Monitoring Boards/Committees: Incyte Corporation, Summit Therapeutics, Research Colloquia: Aptitude Health; Nonrelevant Financial Relationships: Valor (VA).

Hans Lee, MD

Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals,Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc.

Jane Lowe Meisel, MD

Advisory Committees: AstraZeneca Pharmaceuticals LP, GE Healthcare, Novartis, Olema Oncology, Pfizer Inc, Sermonix Pharmaceuticals; Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Olema Oncology, Pfizer Inc, Sermonix Pharmaceuticals; Nonrelevant Financial Relationships: ASCO (DSMB,CDK dosing study).

Shanu Modi, MD 

Advisory Committees: ALX Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Lilly, Nuvation Bio Inc, Pfizer Inc, Seagen Inc; Contracted Research: ALX Oncology, AstraZeneca Pharmaceuticals LP, Avacta Therapeutics, BioNTech SE, BriaCell, D3 Bio, Daiichi Sankyo Inc, Duality Biologics, Genentech, a member of the Roche Group, Nuvation Bio Inc, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: ALX Oncology.

David M O’Malley, MD

Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc,Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics.

Eileen M O’Reilly, MD

Advisory Committees and Consulting Agreements (Uncompensated): Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, IkenaOncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Tango Therapeutics; Contracted Research: Agenus Inc, Amgen Inc, Arcus Biosciences,AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, Tango Therapeutics; Nonrelevant Financial Relationships: American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), Stand Up 2 Cancer.

Joyce O’Shaughnessy, MD

Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, RayzeBio, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC.

Krish Patel, MD

Advisory Committees (All Paid to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck; Consulting Agreements (All Paid to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck, Pfizer Inc, Sanofi; Contracted Research (All Paid to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Immunome, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck.

Daniel P Petrylak, MD

Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Monopteros Therapeutics, Pfizer Inc, pharmaand GmbH, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi, Seagen Inc.

Philip A Philip, MD, PhD

Advisory Committees: Corcept Therapeutics Inc,Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Revolution Medicines Inc; Consulting Agreements: Novocure Inc; Contracted Research: Bristol Myers Squibb, Novartis, Revolution Medicines Inc, Taiho Oncology Inc; Data and Safety Monitoring Boards/Committees: J-Pharma Co Ltd, Oncolytics Biotech Inc.

Zofia Piotrowska, MD, MHS

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Black Diamond Therapeutics Inc, BlossomHill Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Natera Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Summit Therapeutics, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tubulis; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BlossomHill Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Nuvalent, Spectrum Pharmaceuticals Inc, SystImmune Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group.

Noopur Raje, MD 

Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi. 

Richard F Riedel, MD

Advisory Committees and Consulting Agreements: Aadi Bioscience, Adaptimmune, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Cogent Biosciences, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, EMD Serono Inc, GSK, Ipsen Biopharmaceuticals Inc, NANO MRNA, Recordati, Replimune, SpringWorks Therapeutics Inc; Contracted Research: Aadi Bioscience, Adaptimmune, Cogent Biosciences, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, Inhibrx, Intensity Therapeutics, Kura Oncology, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, TRACON Pharmaceuticals Inc; Nonrelevant Financial Relationships: SARC (Sarcoma Alliance for Research through Collaboration).

Gilles Salles, MD, PhD

Advisory Committees: AbbVie Inc, BeOne, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Novartis, Nurix Therapeutics Inc, Pfizer Inc, SERB Pharmaceuticals; Consulting Agreements: AbbVie Inc, Canopy Life Sciences, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Kite, A Gilead Company, ModeX Therapeutics, Treeline Biosciences; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc.

John Strickler, MD

Advisory Committees: AbbVie Inc, Alterome Therapeutics, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cytovation ASA, Daiichi Sankyo Inc, Exelixis Inc, Full-Life Technologies, GE Healthcare, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Leap Therapeutics Inc, Lilly, Merck, Natera Inc, Pfizer Inc, Pheon Therapeutics, Quanta Therapeutics Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tempus, Xilio Therapeutics; Contracted Research: AbbVie Inc, Alterome Therapeutics, Amgen Inc, Apollo Therapeutics, Astellas, Bayer HealthCare Pharmaceuticals, BeOne, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Quanta Therapeutics Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Johnson & Johnson; Stock OPTIONS — Private Companies: Triumvira Immunologics.

Seth Wander, MD, PhD

Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio Inc, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.

Abdulraheem Yacoub, MD

Consulting Agreements: Blueprint Medicines, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research: CTI BioPharma, a Sobi Company, Stemline Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, ADC Therapeutics, Astellas, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, BeOne, Blueprint Medicines, Bristol Myers Squibb, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Johnson & Johnson, Kite, A Gilead Company, Legend Biotech, Lilly, Merck, Natera Inc, Novartis, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, and Summit Therapeutics.

Release date: June 2026
Expiration date: June 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Raje

Jagannath S et al. Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol 2025;43(25):2766-71. Abstract

Kowalski A et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Advances 2025;9(19):4979-86. Abstract

Lee HC et al. Linvoseltamab in patients with relapsed/refractory multiple myeloma in the LINKER-MM1 study: Longer follow-up and subgroup analyses. Clin Lymphoma Myeloma Leuk 2026;26(2):e201-12.e8. Abstract

Mateos M-V et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3. ASH 2025;Abstract LBA-6.

Rasche L et al. Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up. ASCO 2025;Abstract 7528.

Voorhees PM et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7507.

Waldschmidt JM et al. Comprehensive review of bispecific antibody constructs in multiple myeloma: Affinities, dosing strategies and future perspectives. Clin Lymphoma Myeloma Leuk 2025;25(5):309-15. Abstract

 

Dr Lee

Dimopoulos MA et al. DREAMM-8 study of belantamab mafodotin + pomalidomide + dexamethasone vs pomalidomide + bortezomib + dexamethasone in relapsed/refractory multiple myeloma: A high-risk cytogenetic subgroup analysis. EHA 2025;Abstract PF741.

Hajek R et al. Clinical unmet need of lenalidomide-refractory vs non-lenalidomide-refractory patients with multiple myeloma in the HONEUR federated data network. EHA 2025;Abstract PS1745.

Hungria V et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): Updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncology 2025;26(8):1067-80. Abstract

Hungria V et al. Long-term responders from the phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASH 2025;Abstract 2262.

Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract

Lonial S et al. Phase 3 DREAMM-10 study design: Belantamab mafodotin plus lenalidomide and dexamethasone vs daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly-diagnosed multiple myeloma. EHA 2025;Abstract PS1793.

Mateos M-V et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv 2025;9(22):5708-19. Abstract

Terpos E et al. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. Blood 2026;147(14):1574-83. Abstract

Faculty

TARGET AUDIENCE
This program is intended for hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of multiple myeloma (MM).

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.

LEARNING OBJECTIVES

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) MM.
• Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered or recommended.
• Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
• Recall recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
• Analyze the mechanism of action of, published efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators, and use this information to prepare for the potential clinical availability of these agents for patients with R/R MM.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly administered to patients with R/R MM.

ACCREDITATION, SUPPORT AND CREDIT STATEMENT
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity which includes participation in the evaluation components, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

NURSING CONTINUING PROFESSIONAL DEVELOPMENT
Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours and 1.25 contact hours in the area of pharmacology.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/Relapsed-RefractoryMM/Sep4/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

CONTINUING PHARMACY EDUCATION
Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-25-046-H01-P

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
To receive credit for an activity in this series, the participant should review the CME, NCPD or ACPE information, listen to or view the recording, review the downloadable slide set, complete the post-test with a score of 80% or better (CME and NCPD only) and fill out the evaluation. Evaluation location URLs are noted below:
CME Evaluations: ResearchToPractice.com/SOHO2025/RRMM/CME (audio), ResearchToPractice.com/SOHO2025/RRMM/Video/CME (video)
NCPD Evaluations: ResearchToPractice.com/SOHO2025/RRMM/NCPD (audio), ResearchToPractice.com/SOHO2025/RRMM/NCPD/Video (video)
ACPE Evaluations: ResearchToPractice.com/SOHO2025/RRMM/ACPE (audio), ResearchToPractice.com/SOHO2025/RRMM/ACPE/Video (video)

DISCLOSURE & FINANCIAL RELATIONSHIPS POLICY
Medical Learning Institute Inc (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Meletios-Athanasios (Thanos) C Dimopoulos, MD
Professor and Chairman
Plasma Cell Dyscrasias Unit
Section of Hematology and Medical Oncology
Department of Clinical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Alexandra Hospital
Athens, Greece

Advisory Committees, Consulting Agreements and Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma SA, Takeda Pharmaceutical Company Limited.

Hans Lee, MD
Director, Multiple Myeloma Research
Sarah Cannon Research Institute
Nashville, Tennessee

Consulting Agreements: Alexion Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Alexion Pharmaceuticals, Amgen Inc, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc.

Noopur Raje, MD
Director, Center for Multiple Myeloma
Rita Kelley Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi.

SURVEY PARTICIPANTS — Natalie S Callander, MD, has no relevant financial relationships to disclose. Thomas Martin, MD — Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson, Sanofi; Data and Safety Monitoring Boards/Committees: Lilly. Surbhi Sidana, MD — Advisory Committees and Consulting Agreements: AbbVie Inc, Arcellx, BioLineRx, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol Myers Squibb, Janssen Biotech Inc, Magenta Therapeutics, Novartis; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb.

MODERATOR
Joseph Mikhael, MD, MEd
Professor, Clinical Genomics and Therapeutics
Translational Genomics Research Institute (TGen)
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona

Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc, Menarini Group, Sanofi.

PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Release date: October 2, 2025
Expiration date: October 2, 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Raje

Agha ME et al. CARTITUDE-2 cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. EHA 2022;Abstract S185.

Bal S et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). ASH 2024;Abstract 922.

Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.

Frigault MJ et al. Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and/or refractory multiple myeloma: Results from at least 1-year follow-up in all patients. ASH 2023;Abstract 1023.

Hillengass J et al. Ciltacabtagene autoleucel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 biological correlative analyses and updated clinical data. EHA 2022;Abstract P959.

Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. International Myeloma Society 2024;Abstract OA-65.

Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388(11):1002-14. Abstract

San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract

Usmani S et al. KarMMa-2 cohort 2a: Efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. ASH 2022;Abstract 361.

Voorhees PM et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7507.

Dr Lee

Bahlis NJ et al. Talquetamab (tal) + daratumumab (dara) + pomalidomide (pom) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the phase 1b TRIMM-2 study. International Myeloma Society (IMS) 2024;Abstract OA-01.

Baljevic M et al. Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7527.

Banerjee R et al. IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels. Blood Adv 2025;[Online ahead of print]. Abstract

Bumma N et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2024;42(22):2702-12. Abstract

Chari A et al. Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk 2024;24(10):665-93. Abstract

Chari A et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 results from MonumenTAL-1. Blood 2022;140(Suppl 1):384-7. Abstract

Chari A et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387(24):2232-44. Abstract

Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2025;392(2):138-49. Abstract

Cohen Y et al. Talquetamab (tal) + teclistamab (tec) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated phase 1B results from RedirecTT-1 with >1 year of follow-up. IMS 2024;Abstract OA-03.

Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.

Kowalski A et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Adv 2025;[Online ahead of print]. Abstract

Kowalski A et al. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. ASH 2024;Abstract 932.

Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29(9):2259-67. Abstract

Narayan N et al. Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma. JAAD Case Rep 2022;31:66-8. Abstract

Raab MS et al. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) trial. ASH 2024;Abstract 493.

Reese M et al. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol 2024;15:1424925. Abstract

Richter J et al. Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. ASH 2024;Abstract 1021.

Rifkin R et al. Optec: A phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM): Updated results. ASH 2024;Abstract 4753.

Rodriguez-Otero P et al. GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review. Blood Cancer J 2024;14(1):24. Abstract

Tomasson M et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). ASH 2023;Abstract 3385.

Prof Dimopoulos

Bjorklund CC et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 2020;34(4):1197-1201. Abstract

Charliński G et al. Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma. Cancers (Basel) 2021;13(18):4666. Abstract

Dimopoulos MA et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 2025;22(9):680-700. Abstract

Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391(5):408-21. Abstract

Dimopoulos MA et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract LB3440.

Gay F et al. Iberdomide maintenance after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. EHA 2024:Abstract P958.

Hartley-Brown MA et al. Mezigdomide — A novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma. Cancers (Basel) 2024;16(6):1166. Abstract

Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(5):393-407. Abstract

Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.

Hungria VTM et al. Characterization and management of ocular events in patients (Pts) treated with belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study. International Myeloma Society (IMS) 2024;Abstract P-396.

Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int J Hematol 2016;104(3):293-9. Abstract

Liu Y et al. Targeting Ikaros and Aiolos: Reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol 2024;17(8):445-65. Abstract

Lonial S et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022;9(11):e822-32. Abstract

Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). EHA 2021;Abstract S187.

Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the dose-expansion phase of the CC-220-MM-001 trial. Blood 2021;138(Suppl 1):162. Abstract

Mateos M-V et al. Results from DREAMM-7 a randomized phase 3 study of belantamab mafodotin + bortezomib, and dexamethasone vs daratumumab + bortezomib, and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract S214.

Offidani M et al. Belantamab mafodotin for the treatment of multiple myeloma: An overview of the clinical efficacy and safety. Drug Des Devel Ther 2021;15:2401-15. Abstract

Quach H et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. IMS 2024;Abstract P-413.

Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract

Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.

Terpos E et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events. Am J Hematol 2025;100(10):1839-50. Abstract

Trudel S et al. Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial. ASCO 2025;Abstract 7515.

Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.

van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: First results of the phase 2 EMN26 study. ASH 2023;Abstract 208.